Category Archives: Psoriasis

Robin Battles Plaque Psoriasis
Watch Robin #39;s encouraging plaque psoriasis story. Robin lives in California, surrounded by mountains, but found herself covering up when venturing outside to...

By: PsoriasisMatters

View original post here:
Robin Battles Plaque Psoriasis - Video

Dr .Ambalkar #39;s psoriasis treatment hindi Video

By: Vaibhav Pawar

More:
Dr .Ambalkar's psoriasis treatment hindi Video - Video

Healthy Living with Dr. Jitka Lom: UNDERSTANDING PSORIASIS (1 of 2)
DescriptionDr. Jitka Lom with ExpressCare shares expert advice on medicine and healthy island living.

By: kuamnews

Read the original:
Healthy Living with Dr. Jitka Lom: UNDERSTANDING PSORIASIS (1 of 2) - Video

By RTT News, March 21, 2014, 02:45:00 AM EDT

(RTTNews.com) - Novartis ( NVS ) announced Friday that a new phase IIIb head-to-head study of IL-17A inhibitor secukinumab (AIN457) versus Stelara or ustekinumab in moderate-to-severe plaque psoriasis has started patient enrollment.

The company stated that a total of twenty-five secukinumab abstracts, including two pivotal phase III convenience studies to be presented for the first time, will be unveiled at the 72nd Annual Meeting of the American Academy of Dermatology or AAD, taking place in Denver, Colorado, USA from 21-25 March 2014.

"We are pleased to announce the start of CLEAR, our global phase IIIb head-to-head psoriasis study of secukinumab versus Stelara at the 2014 AAD annual meeting, which will provide further evidence regarding the benefit IL-17A inhibitor secukinumab brings to patients," said Tim Wright, Global Head of Development, Novartis Pharmaceuticals.

CLEAR (Comparison to assess Long-term Efficacy, sAfety and toleRability of secukinumab vs. ustekinumab), the new 52-week, multicenter, randomized, double-blind study, is the second head-to-head phase III study initiated with secukinumab, and will compare the long-term safety, tolerability and efficacy of secukinumab versus Stelara, a current standard-of-care therapy, in patients with moderate-to-severe plaque psoriasis.

The target enrollment for this global phase IIIb study is approximately 640 patients with sites in 25 countries across North America, Europe, Asia and Australia.

The primary endpoint measured at Week 16 is at least 90% reduction in the severity of psoriasis symptoms (redness, thickness and scaling) and the extent of skin affected by the disease, known as Psoriasis Area and Severity Index (PASI) 90. PASI 90 is considered the best evidence of efficacy and is therefore a more robust measure of the extent of skin clearance compared to the standard efficacy measures used in most psoriasis clinical studies.

The CLEAR study follows the pivotal phase III head-to-head FIXTURE study, which showed secukinumab was significantly superior to Enbrel in clearing skin. Enbrel is a current standard-of-care anti-TNF-alpha medication approved to treat moderate-to-severe plaque psoriasis, and results from the FIXTURE study were first announced in October 2013.

For comments and feedback: contact editorial@rttnews.com

http://www.rttnews.com

See more here:
Novartis Starts Secukinumab Vs Stelara Phase IIIb Head-to-head Psoriasis Study

Article updated: 3/20/2014 10:51 AM

North Chicago-based AbbVie has started testing to evaluate the use of Humira as a treatment for fingernail psoriasis in patients with moderate to severe chronic plaque psoriasis, an area of unmet need.

Currently there are no approved treatments for fingernail psoriasis.

Since treatment options are limited, we welcome research that evaluates new options for patients suffering from this disease and are excited to start evaluating adalimumab in this patient population, said Dr. Phoebe Rich, M.D., clinical adjunct professor of dermatology at Oregon Health Sciences University.

Psoriasis is a noncontagious, chronic immune disease that speeds the growth cycle of skin cells and results in thick, scaly areas of skin. Psoriasis can also affect the fingernails causing pitting, discoloration, loosening and irregular contour of the fingernail. Although the prevalence of fingernail psoriasis in those with moderate to severe chronic plaque psoriasis is unknown, about 50 percent of the 125 million people worldwide with psoriasis have nail involvement.

Humira is currently originally developed for the treatment of rheumatoid arthritis in adults, but has erecently been expanded to treat moderate to severe ulcerative colitis and moderate to severe chronic plaque psoriasis.

Read this article:
AbbVie to test Humira for treatment of fingernal psoriasis

Healthy Living with Dr. Jitka Lom: UNDERSTANDING PSORIASIS (2 of 2)
Dr. Jitka Lom with ExpressCare shares expert advice on medicine and healthy island living.

By: kuamnews

Read the original post:
Healthy Living with Dr. Jitka Lom: UNDERSTANDING PSORIASIS (2 of 2) - Video

Psoriasis Free For Life Guide Order
Psoriasis Free For Life by Katy Wilson ebook download: http://tinyurl.com/PsoriasisFreeForLifeDownloads Psoriasis Free For Life is the a natural, permanent a...

By: Psoriasis Free For Life book download

See the article here:
Psoriasis Free For Life Guide Order - Video

Psoriasis, causes, treatment, management
Description.

By: EntoVerm

Read the original:
Psoriasis, causes, treatment, management - Video

Psoriasis Special on Arogya Mantra (Epi 13 part 2) - Dr. Chauhan #39;s TV Show on IBN7
Jiva Ayurveda provides authentic Ayurvedic treatment and medicines for all kinds of chronic diseases and conditions such as diabetes, arthritis, stress, migr...

By: Jiva Ayurveda

Read the original post:
Psoriasis Special on Arogya Mantra (Epi 13 part 2) - Dr. Chauhan's TV Show on IBN7 - Video

Believa Natural Intensiv - Die Pflege bei Neurodermitis oder Psoriasis (Schuppenflechte)
Klinische Studie belegt Wirksamkeit bei Neurodermitis und Psoriasis (Schuppenflechte). Die therapiebegletende Pflegecreme damit Ihre Haut zur Ruhe kommt. Bel...

By: Believa GmbH

See the rest here:
Believa Natural Intensiv - Die Pflege bei Neurodermitis oder Psoriasis (Schuppenflechte) - Video